Sarah Valencia

478 total citations · 1 hit paper
22 papers, 271 citations indexed

About

Sarah Valencia is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Sarah Valencia has authored 22 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 6 papers in Infectious Diseases and 5 papers in Immunology. Recurrent topics in Sarah Valencia's work include Cytomegalovirus and herpesvirus research (15 papers), Herpesvirus Infections and Treatments (12 papers) and Parvovirus B19 Infection Studies (5 papers). Sarah Valencia is often cited by papers focused on Cytomegalovirus and herpesvirus research (15 papers), Herpesvirus Infections and Treatments (12 papers) and Parvovirus B19 Infection Studies (5 papers). Sarah Valencia collaborates with scholars based in United States, Austria and Germany. Sarah Valencia's co-authors include Lindsey Hutt‐Fletcher, Sallie R. Permar, Henri‐Jacques Delecluse, Matthew R. Hicks, Celine Schelcher, Alison J. Sinclair, Liudmila S. Chesnokova, Jennifer A. Jenks, Timothy F. Kowalik and Jason D. Marshall and has published in prestigious journals such as Journal of Virology, The Journal of Infectious Diseases and PLoS Pathogens.

In The Last Decade

Sarah Valencia

21 papers receiving 265 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine

2024 48 citations Xintao Hu, Sarah Valencia et al. The Journal of Infectious Diseases profile →

Peers

Countries citing papers authored by Sarah Valencia

Since Specialization

Citations

This map shows the geographic impact of Sarah Valencia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Valencia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Valencia more than expected).

Fields of papers citing papers by Sarah Valencia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Valencia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Valencia. The network helps show where Sarah Valencia may publish in the future.

Co-authorship network of co-authors of Sarah Valencia

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Valencia. A scholar is included among the top collaborators of Sarah Valencia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Valencia. Sarah Valencia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SARS-COV-2 MRNA VACCINE IMMUNOGENICITY IN SLE 2025 ·The Journal of Rheumatology ·Rebecca E. Sadun, (unknown), Sarah Valencia, Emmanuel B. Walter, M. Anthony Moody	0
2	Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine breakdown → 2024 ·The Journal of Infectious Diseases ·Xintao Hu, (unknown), (unknown), Sarah Valencia, Jennifer A. Jenks, (unknown), (unknown), M. Connors, Justin Pollara, Caroline Andy, (unknown), Emmanuel B. Walter, Kathryn M. Edwards, David I. Bernstein, (unknown), Matthew Koch, Lori Panther, Andrea Carfı́, Kaichun Wu, Sallie R. Permar	48
3	Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth 2024 ·npj Vaccines ·(unknown), Leike Li, Cody S. Nelson, Richard Barfield, Sarah Valencia, Cliburn Chan, Hiromi Muramatsu, Paulo J.C. Lin, Norbert Pardi, Zhiqiang An, Drew Weissman, Sallie R. Permar	8
4	Use of Electronic Nicotine Delivery Systems and Age of Asthma Onset Among US Adults and Youths 2024 ·JAMA Network Open ·Adriana Pérez, Sarah Valencia, (unknown), Melissa B. Harrell	6
5	Mathematical Modeling of Rhesus Cytomegalovirus Transplacental Transmission in Seronegative Rhesus Macaques 2023 ·Viruses ·(unknown), (unknown), (unknown), Sarah Valencia, Alice F. Tarantal, Amitinder Kaur, Sallie R. Permar, Cliburn Chan	1
6	Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection 2023 ·npj Vaccines ·Sarah Valencia, (unknown), (unknown), Maria Dennis, (unknown), Bhavna Hora, Amit Kumar, (unknown), Leike Li, Daniel C. Freed, Ningyan Zhang, Zhiqiang An, Dai Wang, Sallie R. Permar	2
7	Protective effect of pre-existing natural immunity in a nonhuman primate reinfection model of congenital cytomegalovirus infection 2023 ·PLoS Pathogens ·(unknown), Shan Yu, (unknown), Frances M. Saccoccio, (unknown), Daniel Malouli, Anne M. Mirza, Sarah Valencia, Margaret H. Gilbert, Robert V. Blair, Scott G. Hansen, Peter A. Barry, Klaus Früh, Jeffrey D. Jensen, Susanne P. Pfeifer, Timothy F. Kowalik, Sallie R. Permar, Amitinder Kaur	5
8	A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus 2023 ·PLoS Pathogens ·Jennifer A. Jenks, (unknown), (unknown), Amit Kumar, Daniel Wrapp, (unknown), (unknown), (unknown), Sarah Valencia, M. Connors, (unknown), Bhavna Hora, (unknown), Jason S. McLellan, Kevin Wiehe, Sallie R. Permar	4
9	Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus 2022 ·The Journal of Infectious Diseases ·(unknown), Maria Dennis, (unknown), Sarah Valencia, (unknown), Eleanor C. Semmes, (unknown), Jennifer A. Jenks, Richard Barfield, Justin Pollara, Cliburn Chan, Christian Sinzger, Sallie R. Permar	5
10	Clinical factors associated with cytomegalovirus shedding among seropositive pregnant women 2022 ·American Journal of Obstetrics & Gynecology MFM ·(unknown), (unknown), Jeremy M. Weber, Sarah Valencia, Alaattin Erkanli, Sarah K. Dotters‐Katz, Sallie R. Permar, Brenna L. Hughes	4
11	Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP 2021 ·Human Vaccines & Immunotherapeutics ·Sarah Valencia, (unknown), Alexander Marin, (unknown), (unknown), (unknown), Chelsea Sanders, Simone Difilippantonio, Reinhard Kirnbauer, Richard B.S. Roden, Lígia A. Pinto, Robert H. Shoemaker, Alexander K. Andrianov, Jason D. Marshall	14
12	Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models 2021 ·Vaccine ·(unknown), Sarah Valencia, Amit Kumar, Cliburn Chan, Maria Dennis, (unknown), Angela Woods, Shinu John, Andrea Carfı́, Sallie R. Permar	10
13	Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine 2021 ·Nanomedicine Nanotechnology Biology and Medicine ·Alexander Marin, (unknown), Sarah Valencia, (unknown), Reinhard Kirnbauer, Richard B.S. Roden, Lígia A. Pinto, Robert H. Shoemaker, Jason D. Marshall, Alexander K. Andrianov	14
14	Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity 2021 ·Viruses ·(unknown), Sarah Valencia, Susanne P. Pfeifer, Jeffrey D. Jensen, Timothy F. Kowalik, Sallie R. Permar	20
15	Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection 2020 ·Virology ·(unknown), (unknown), (unknown), Jennifer A. Jenks, Cody S. Nelson, (unknown), (unknown), Sarah Valencia, Justin Pollara, W. Daniel Edwards, Jason S. McLellan, Daniel Wrapp, Tong‐Ming Fu, Ningyan Zhang, Daniel C. Freed, Dai Wang, Zhiqiang An, Sallie R. Permar	12
16	Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists 2020 ·Vaccine ·(unknown), Erin Harberts, Sarah Valencia, (unknown), Chelsea Sanders, Akshay Jain, Nicholas R. Larson, C. Russell Middaugh, William D. Picking, Simone Difilippantonio, Reinhard Kirnbauer, Richard B.S. Roden, Lígia A. Pinto, Robert H. Shoemaker, Robert K. Ernst, Jason D. Marshall	20
17	Vaccines for Perinatal and Congenital Infections—How Close Are We? 2020 ·Frontiers in Pediatrics ·Tulika Singh, (unknown), (unknown), Sarah Valencia, Ashley N. Nelson, Sallie R. Permar	13
18	Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model 2018 ·Vaccine ·Sarah Valencia, Rachel Gill, Kennichi Dowdell, Yanmei Wang, (unknown), (unknown), (unknown), Jeffrey I. Cohen	10
19	The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection 2016 ·Virology ·Liudmila S. Chesnokova, Sarah Valencia, Lindsey Hutt‐Fletcher	14
20	Mutation of a Single Amino Acid Residue in the Basic Region of the Epstein-Barr Virus (EBV) Lytic Cycle Switch Protein Zta (BZLF1) Prevents Reactivation of EBV from Latency 2005 ·Journal of Virology ·Celine Schelcher, Sarah Valencia, Henri‐Jacques Delecluse, Matthew R. Hicks, Alison J. Sinclair	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact